Wells Fargo’s Argos Therapeutics, Inc. ARGS Stock Holding History

Wells Fargo’s Portfolio ARGS Stock Details ARGS Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2017 Q2	–	Sell	-617	Closed	-$6K	–	6763
2017 Q1	$6K	Buy	617 +60	+11%	+$3.8K	﹤0.01%	6012
2016 Q4	$55K	Hold	557	–	–	﹤0.01%	5354
2016 Q3	$55K	Buy	557 +528	+1,821%	+$55.2K	﹤0.01%	5259
2016 Q2	$4K	Buy	+29	New	+$3.87K	﹤0.01%	5884

Other funds holding ARGS

Pharmstandard International Luxembourg $29M AUM 3.25% 1-Year Est. Return

Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return

Millennium Management New York $240B AUM 35.51% 1-Year Est. Return

SMH

Sanders Morris Harris Houston, Texas $172M AUM 22.54% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

California Public Employees Retirement System Sacramento, California $162B AUM 25.78% 1-Year Est. Return

Wedbush Securities Los Angeles, California $3.43B AUM 24.13% 1-Year Est. Return

ECM

Element Capital Management New York $1.05B AUM 5.05% 1-Year Est. Return

Stifel Financial St. Louis, Missouri $109B AUM 21.36% 1-Year Est. Return

Wells Fargo's ARGS Position: Q2 2017 in Review

Wells Fargo sold out of Argos Therapeutics, Inc. (ARGS) in Q2 2017, closing a stake of 617 shares — an estimated $6K sold.

Wells Fargo first reported a position in ARGS in Q2 2016 and held it in 4 quarters. The position peaked at $55K in Q4 2016. 34 funds tracked by Wall St. Rank hold ARGS as of Q2 2017.

Wells Fargo reported no remaining Argos Therapeutics, Inc. position as of Q2 2017 after selling out during the quarter.
Wells Fargo sold 617 Argos Therapeutics, Inc. shares in Q2 2017, an estimated $6K.
Wells Fargo first reported a position in Argos Therapeutics, Inc. in Q2 2016 and held it in 4 quarters.
Wells Fargo's Argos Therapeutics, Inc. position peaked at $55K in Q4 2016.
34 funds tracked by Wall St. Rank held Argos Therapeutics, Inc. as of Q2 2017.

Based on Wells Fargo's 13F filing for Q2 2017, filed 10 Aug 2017.